Evidence from the TRAIN-2 and KRISTINE trials suggested that the order of HER2-targeted therapy and chemotherapy can influence outcomes, with early introduction of HER2 blockade potentially improving tumor eradication and reducing toxicity [12,13]. The gene discussed is ERBB2; the disease is neoplasm.